Ono Pharmaceutical’s Stock on the Rise, Merus N.V. Reports Promising Cancer Treatment Results
Ono Pharmaceutical Co Ltd has seen a moderate increase in its stock price over the past year, with a recent high of 2219.5 JPY and a low of 1474 JPY. This steady growth is a testament to the company’s strong financial position, as evidenced by its substantial market capitalization.
While Ono Pharmaceutical’s stock has been performing well, its partner Merus N.V. has made significant strides in the field of cancer treatment. In the second quarter of 2025, Merus reported positive financial results, which are expected to support the company’s operations through at least 2028. This development has the potential to benefit Ono Pharmaceutical through their partnership.
Merus’ cancer treatment, Petosemtamab, in combination with Pembrolizumab, has shown promising efficacy in a phase II trial. The results are impressive, with a 63% response rate and 79% overall survival rate at 12 months. These numbers indicate that Petosemtamab, in combination with Pembrolizumab, is a highly effective treatment option for patients.
Key Highlights:
- Ono Pharmaceutical’s stock price has increased moderately over the past year
- Merus N.V. has reported positive financial results for the second quarter of 2025
- Petosemtamab, in combination with Pembrolizumab, has shown a 63% response rate and 79% overall survival rate at 12 months in a phase II trial
- Merus’ operations are expected to be supported through at least 2028, potentially benefiting Ono Pharmaceutical through their partnership